Peptide payment processing, explained.

A processor prices your account on what it expects to lose, not on whether your business is legal. Peptides raise that number for reasons that have little to do with the compounds themselves.

Three things drive it. The federal picture around research peptides is unsettled and moved twice in the last year, so a risk team cannot point to a stable rule and plan around it. What a peptide product is treated as depends heavily on how it is sold, which means one product page can change the answer. And research compounds bought online carry the refund and dispute behavior of any purchase where the buyer is not sure what turned up in the box.

None of that is a verdict on your business. It is a description of the uncertainty a payment company is being asked to hold. Read it that way and the problem gets more workable, because uncertainty is something you can reduce with documents. A verdict is not.

Almost no processor bans peptides in writing. That sounds like good news, and it is the trap.

Of the eight processors whose published lists we track, Wise is the only one that names them flatly, prohibiting "anabolic steroids and peptides." Adyen names "peptides, research chemicals" inside hazardous materials, restricted for business-to-business sales and prohibited when the same goods are sold direct to consumers. Stripe's nearest entry covers "incorrectly labeled research chemicals," so the line turns on your labeling rather than on the product. PayPal names steroids, which is a different class of compound. Square's list of unsupported industries does not mention peptides at all, and Square still terminated a peptide seller in August 2026.

So the category list is not where the exposure sits. Every processor agreement already lets the company end the relationship at its own judgment, and that clause closes most peptide accounts. You can read each policy word for word in our prohibited businesses lookup. Why processors decline peptide sellers works through the gap between the written rule and the reviewer's decision.

Underwriting reads your store, not your category. The question a reviewer answers is whether the whole offer agrees with the way you have labeled it.

Research-use-only labeling, age-gating at checkout, certificates of analysis, and the absence of dosing or human-consumption language are the things that get checked. That is a statement about payment risk and not about law. None of those choices makes a product legal, compliant, or permissible to sell. What they do is show a reviewer that the business has thought about its own exposure, which is exactly what an empty file cannot show.

Two more items decide more cases than sellers expect. The first is what else is in the catalog, because a mixed catalog gets underwritten on its riskiest item. The second is your refund and dispute history, since most peptide accounts get opened for review because a number moved, not because somebody browsed the site. Certificates of analysis covers what a reviewer reads on a lab report, and research-use-only labeling covers what the disclaimer carries and what it does not.

None of the 2026 peptide news changes what you can sell or how a processor reads your store. It is worth knowing anyway, because sellers keep citing it in applications where it does not help.

The FDA keeps a list of bulk drug substances that compounding pharmacies may use under section 503A. Nineteen peptides were moved to Category 2 in September 2023, the tier for substances the agency has identified significant safety risks for. On April 15, 2026 the FDA said it would remove twelve peptides from Category 2 because the nominations behind them had been withdrawn. Removal is not permission. It does not place a substance on the list or into Category 1, and a peptide on neither list still cannot be legally compounded.

Then on July 23 and 24, 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding six peptides, including BPC-157, TB-500 and Semax. The votes were narrow and FDA staff opposed them. That committee only advises. The FDA has not adopted the recommendation, and rulemaking after a vote like this can take more than a year. A further review of five more peptides is scheduled before the end of February 2027.

All of it applies to licensed pharmacies compounding for patients with prescriptions. That is a different business from selling research compounds online. Whether a specific product is lawful for you to sell is a question for your own lab and your own counsel.

GLP-1s are not research peptides and a processor will not treat them as one. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, which closed the compounding route that had depended on shortage status. Enforcement discretion then ended on a staggered schedule across 2025, finishing in May of that year. A business selling compounded GLP-1s today sits in a different position from a research-use seller, and the underwriting conversation is different too.

SARMs are their own case, and a harder one. They are not dietary supplements and never were. The FDA treats them as unapproved new drugs, and its warning letters say plainly that labeling them as supplements to work around FDA review is illegal. Letters were still going out in December 2025. If SARMs are in your catalog, expect them to set the terms for everything else you sell.

A shutdown is a sequence, and the first week decides most of what follows. Two facts matter more than the wording of the notice. Where your money is and when it releases, and whether your old processor reported you to a terminated merchant file.

That report is the part that follows you. Listings stay active for five years, and only the acquiring bank that filed one can correct or remove it (Stripe, terminated merchant files). There is no direct merchant appeal. The reason code filed against you shapes your options more than your industry does, which is why finding out your status comes before applying anywhere else. Applying blind and collecting declines leaves a trail that makes the next application harder.

A listing narrows who can place you. It does not end card processing. Peptide merchant account terminated covers the first week in order, the account shutdowns hub covers the sequence in general, and MATCH and TMF options covers what is still available once you are listed.

A workable setup is a dedicated merchant account, underwritten for this category on purpose, before the first transaction rather than after the first flag.

That means your own merchant identification number instead of a slot inside somebody else's pooled account. It means the labeling posture, the lab records, the age-gating and the dispute profile all get read up front. The compliance questions get settled while you still have room to fix them, instead of arriving as an account closure six months in. Midnight Payments prices these accounts per business from what your business actually does, not from a rate card, with no long-term contract and the rate, any reserve structure, and the settlement timing set out in writing before you sign. US, Canadian, and international peptide sellers are accepted, with no minimum monthly volume.

One warning is worth carrying out of this whole topic. Any offer promising approval regardless of your history is telling you it did no underwriting, and an account nobody underwrote is the same product that just closed on you. If you sell research peptides or SARMs and want a real review, start your application and tell us your catalog, your monthly volume, and what happened with your last processor. We price the payment risk. The legal questions stay with your lab and your counsel, where they belong.